Though the association with response to EGFR-targeted therapy in mCRC and loss of PTEN expression does not appear to be as strongly correlated as response and PIK3CA mutations [53], the consideration of both tumor PTEN expression status and PIK3CA mutation status may contribute to predicting response to EGFR-targeted therapies in SCCHN. Here, EGFR is linked to neoplasm.